Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of ATO clinical trial patients

ABSTRACT: RNAseq of ATO trial

PROVIDER: PRJEB20631 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1957640_1.fastq.gz	Fastqsanger.gz
	ERR1957640_2.fastq.gz	Fastqsanger.gz
	ERR1957650_1.fastq.gz	Fastqsanger.gz
	ERR1957650_2.fastq.gz	Fastqsanger.gz
	ERR1957641_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

GOYA DLBCL clinical trial - RNASeq dataset

Project description:This dataset contains collected RNASeq data of 552 samples from the GOYA clinical trial.

2019-02-01 | GSE125966 | GEO

Single-Cell RNA-Sequencing facilitates the effectiveness analysis of ATO and DAC co-treatment in PBMCs from PANDA-T0 trial

Project description:The goals of this study is to reveal the transcriptome of structural p53 mutations rescued by ATO and DAC in AML/MDS patients.

2024-07-31 | GSE269125 | GEO

Gene expression profiling by RNA-seq of newly diagnosed multiple myeloma patients included in the HOVON95 clinical trial

Project description:This gene expression set contains data from patients included in the HOVON95 clinical trial. Using this data the technical comparison between microarray and RNAseq was made.

2022-06-01 | GSE164847 | GEO

GOYA DLBCL clinical trial - RNASeq dataset

Project description:GOYA DLBCL clinical trial - RNASeq dataset

| PRJNA518119 | ENA

Clinical Trial Sequencing Project (CTSP)

Project description:Clinical Trial Sequencing Project (CTSP)

| PRJNA331220 | ENA

Gene expression signatures for combined ATO and CDDP treatment (Ato-C) in CML cell lines

Project description:To investigate the effect of Ato-C on gene expression, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to suppress the cell proliferation of Ph+ CML cell lines. K562, KU-812 and MEG-A2 cells were treated with ATO, CDDP or Ato-C for 24 h in vitro.

2017-10-12 | GSE104813 | GEO

Single-Cell RNA-Sequencing facilitates the effectiveness analysis of clinical-dose arsenic trioxide (ATO) treatment in reactivating V272M in AML patient and in primary AML PBMCs

Project description:The goals of this study is to reveal the transcriptome of p53-V272M rescued by ATO in AML patient and in primary AML PBMCs

2024-08-01 | GSE182926 | GEO

Gene expression profiles of ATO-treated and negative control cells

Project description:Gene expression profile changes between ATO- treated and DMSO- treated Huh7 and Hep3B cells were analyzed To further explore the mechanism of ATO-induced differentiation, we performed a gene microarray assay to compare the differential gene expression profiles of low-dose ATO-treated (3 μM ATO treatment for 7 days) and negative control cells.

2019-07-01 | GSE128517 | GEO

Gene expression from total and polysomal RNA fractions after ATO treatment in LN229 cells.

Project description:Arsenic trioxide (ATO) treatment leads to activation of mRNA translation through the MAPK-interacting kinase (MNK) signaling pathway. Polysomal fractionation and microarray analysis allows for identification of transcripts undergoing active translation. We identified the genes differentially enriched in untreated and ATO treated fractions. In this dataset, we include expression data in untreated and ATO treated LN229 cells using either the total or polysomal RNA.

2018-01-01 | GSE100523 | GEO

Single-Cell RNA-Sequencing facilitates the effectiveness analysis of ATO and DAC co-treatment in PBMCs from PANDA-T0 trial

Project description:Single-Cell RNA-Sequencing facilitates the effectiveness analysis of ATO and DAC co-treatment in PBMCs from PANDA-T0 trial

| PRJNA1120357 | ENA